Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study

Xu Song1,*, Yu Jiang2,*, Chunjuan Ren1, Xun Sun1, Qiang Zhang3, Tao Gong1, Zhirong Zhang1

1Key Laboratory of Drug Targeting and Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, 2Center for Drug Evaluation, State Food and Drug Administration, 3State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Peking, People’s Republic of China

*These authors contributed equally to this work

Background: The clinical application of nimodipine (NIM) is limited by several unfavorable properties, which are induced by its low aqueous solubility. In the present study, nimodipine-loaded egg phosphatidylcholine-sodium glycocholate mixed micelles (NIM-EPC-SGC-MMs) were prepared to improve the water solubility of NIM, thus allowing it to be more applicable for clinical use.

Methods: NIM-EPC-SGC-MMs were prepared using the coprecipitation method and the factors influencing formulation quality were optimized. After formulation, water solubility, solubilizing efficiency, drug loading, particle size, physical compatibility, pharmacokinetics, and vascular irritability were determined.

Results: The mean size of the NIM-EPC-SGC-MMs was 6.099 ± 0.048 nm under optimized conditions. The water solubility of NIM in EPC-SGC-MMs was enhanced 250-fold compared with free NIM. The physical compatibility, pharmacokinetic, and vascular irritability studies showed that, in comparison to the commercially available NIM injections, NIM-EPC-SGC-MMs presented better physical compatibility, the same pharmacokinetic profile, and less risk of local vascular irritation and phlebitis.

Conclusion: EPC-SGC-MMs represent a promising new formulation suitable for the intravenous delivery of NIM.

Keywords: drug loading, nimodipine injection, physical compatibility, solubilizing efficiency

Introduction

Nimodipine (NIM) is a 1,4-dihydropyridine calcium channel blocker (Figure 1), which has been shown to dilate cerebral arterioles and increase cerebral blood flow.1 It has been reported to possess beneficial pharmacological activity in the treatment of a range of cerebrovascular disorders.1,2 The therapeutic use of NIM includes that in subarachnoid hemorrhage, focal or global ischemia, and epilepsy.2,3 Presently, NIM is also used for acute ischemic stroke, migraines, cerebral vasospasm, multi-infarct dementia, and hypotension-induced memory impairment.4–9 Despite the promising biological effects of NIM, its clinical performance is restricted by its low oral bioavailability (as low as 10%) and low aqueous solubility (3.86 µg/mL).9,10 Thus, intravenous administration is the alternative route for NIM in case of efficacy. To achieve a sufficient NIM concentration, a commercial injection of NIM has been produced by solubilizing NIM with about 40% solvent mixture: 23.7% (v/v) ethanol and 17% (v/v) polyethylene glycol 400.11 However, this concentration has many noticeable drawbacks when applied in the clinic. For instance, according to the intravenous dosage regimen, this formulation...
requires a time-consuming administration (about 10 hours by infusion care), as well as special equipment and additional nursing care. Further, NIM-ethanol injections may cause local adverse reactions at the administration site, such as pain and inflammation. Of more concern, there may be phlebitis during infusion and poor patient compliance. In addition, crystallization caused by the poor water solubility of NIM can also occur when the NIM injection is diluted by injection solutions, which is dangerous to patients. Consequently, the application of these NIM commercial injections has been limited by their high medication cost, low patient compliance, and safety considerations.

Thus, there is a pressing need to develop a safe, injectable formulation for NIM by means of pharmaceutics. Based on its physiological compatibility and solubilizing capacity, a phosphatidylcholine (PC)-bile salts (BS)-mixed micelle (MM) formulation is an attractive candidate for the intravenous administration of poorly soluble drugs. This simple approach of combining a water-soluble surfactant with a water-insoluble phospholipid results in an isotropically clear solution. Many studies have been published regarding the preparation and characterization of PC-BS-MMs. BS present in bile with a high concentration can solubilize PC to a large extent, forming a kind of clear mixed-micellar solution that in turn can solubilize substances with poor water solubility. With the solubilized phospholipids, the hemolytic effects of BS can be neutralized. Most importantly, PC-BS-MMs have been proven to be locally and systemically well tolerated, with no embryotoxic, teratogenic, or mutagenic effects after administration. Without a toxicologically solvent mixture, a PC-BS-MM formulation can reduce irritation and improve the patient compliance. Consequently, PC-BS-MMs are an ideal drug carrier for the intravenous administration of NIM.

In this study, our objective was to develop a novel potential delivery vehicle for NIM that could be used in the clinic. First, we prepared and characterized NIM-loaded egg phosphatidylcholine (EPC)-sodium glycocholate (SGC)-mixed micelles (MMs). We then compared and studied the pharmacokinetic properties of NIM-EPC-SGC-MMs versus NIM injection. We also compared the physical compatibility of the infusion solutions and the intravenous irritation of NIM-EPC-SGC-MMs compared with NIM injection.

**Materials and methods**

**Reagents and chemicals**

NIM was kindly supplied by Chongqing Yaoyou Pharmaceutical Co, Ltd (Chongqing, China). EPC (purified ovolecithin), purity 80%, was obtained from Lipoid GmbH (Ludwigshafen, Germany). Pyrene was purchased from Sigma Aldrich (Munich, Germany) and used without further purification. SGC was a gift from Chongqing Yaoyou Pharmaceutical Co, Ltd. The commercially available NIM injection (0.2 mg/mL, batch number: 110101) was purchased from Ya Bao Pharmaceutical Group Co, Ltd (Shanxi, China). Reference substances of nitrendipine (number: 100585-200602) and NIM (number: 100270-200002) were purchased from Chengdu Rong Jin Medical Technology Development Co, Ltd (Chengdu, China). Sodium chloride injection (batch number: 1191022) was purchased from Taiji Group Southwest Pharmaceutical Co, Ltd (Chongqing, China). Double-distilled (DI) water and the other chemical reagents were of analytical grade or better.

**Animals**

Male Wistar rats (weight 200 ± 20 g) and Japanese big-ear rabbits (weight 2.5–3.0 kg) were provided by the Laboratory Animal Center of Sichuan University (Chengdu, China). The protocols and procedures were recognized by the Institutional Animal Care and Use Committee of Sichuan University.

**Preparation of NIM-EPC-SGC-MMs**

Due to the good solubility of NIM, SGC, and EPC in anhydrous ethanol, NIM was easily loaded into PC-BS-MMs using the coprecipitation method. Briefly, NIM, SGC, and EPC (at different molar ratios and concentrations) were dissolved by anhydrous ethanol in a 25 mL round-bottom flask. The organic solvent was evaporated at 60°C under vacuum to form a thin film that was then rehydrated in physiological saline and dispersed by slight shaking before the pH was adjusted to about 7.4. To remove the unloaded drug, the solution was centrifuged at 10,000 × g in an Allegra X-22R Centrifuge with a F2402H rotor (Beckman Coulter Inc, Brea, CA) for 5 minutes and the supernatant containing freshly formed MMs was collected.
Based on the single-factor method, a high-quality formulation was obtained by optimizing several main formulation factors, including the ratio of the mass concentration of EPC and SGC, the total concentration of EPC and SGC, the dose of NIM, and the pH value of dispersed medium. Each experiment was run in triplicate.

**Critical micelle concentration (CMC) determination**
The CMC of the binary mixture of EPC-SGC (the optimal ratio) in DI water was determined by the pyrene 1:3 ratio method.\(^2\)\(^9\) Samples of MMs of different concentrations ranging from 4% to 1 × 10\(^{-2}\)% were prepared. Pyrene, dissolved in methanol, was added to EPC-SGC-MMs with different concentrations to obtain a final concentration of 4 × 10\(^{-7}\) mol/L. The mixtures were balanced for 24 hours in a dark room at room temperature before measurement and plated in 96-well plates for fluorescence measurements (using a Fluoroskan Ascent FL; Thermo Scientific, Waltham, MA). Fluorescence emission spectra of pyrene were obtained using an excitation wavelength of 336 nm, with an emission slit of 5 nm. The intensities, I\(_{336}\) and I\(_{372}\), were measured at the wavelengths corresponding to the first and third vibronic bands located near 372 and 383 nm. All fluorescence measurements were carried out at 25°C. Experiments were performed in triplicate. The ratio of I\(_{336}\) to I\(_{372}\) for pyrene was 1:3.\(^2\)\(^9\) The pyrene 1:3 ratio data were analyzed with Origin 8.5 software (OriginLab Corp, Northampton, MA).

**Measurement of particle size**
The particle size and polydispersity index of the formed optimal MMs were measured by dynamic light scattering (Malvern Zetasizer Nano ZS90, Malvern Instruments Ltd, Malvern, UK) at 25°C. The samples were measured with no dilution.

**Transmission electron microscopy**
The morphology of optimum NIM-EPC-SGC-MMs was observed with a field-emission high-resolution transmission electron microscope (TEM) (Technai G\(^\text{F}\) F20, FEI, Eindhoven, The Netherlands). The sample was placed on copper grids and stained with 2% (w/v) phosphotungstic acid for 30 seconds. After the excess solution was drawn off and the sample was allowed to dry, it was subjected to TEM observation.

**Drug solubility, solubilizing efficiency, and drug loading of NIM-EPC-SGC-MMs**
The concentration of the NIM solubilized by optimal EPC-SGC-MMs was determined by reverse-phase high-performance liquid chromatography (HPLC) on three parallel measurements. After dilution with methanol, the NIM-EPC-SGC-MMs were injected into an HPLC system. The analysis was performed on an Agilent 1260 infinity LC system (with a G1329B autosampler, G1312B pump, and G1314B detector; Agilent Technologies, Inc, Santa Clara, CA), equipped with a Kromasil C18 column (250 × 4.6 mm, 5 μm; Bohus, Sweden) kept at 40°C as the stationary phase. The analysis parameters for NIM were as follows: the mobile phase consisted of a mixture of methanol, acetonitrile, and DI water (35:38:27); the injection volume of the samples and standards was 20 μL; the flow rate was set at 1.0 mL/min, and the detection wavelength was 237 nm by ultraviolet detection.

Solubilizing efficiency and drug loading (DL%) were calculated by the following equations:

\[
\text{Solubilizing efficiency (\%)} = \frac{(\text{Weight of NIM in micelles} / \text{Weight of NIM feeding}) \times 100\%}{(1)}
\]

\[
\text{DL\%} = \frac{(\text{Weight of NIM in micelles}/\text{Weight of feeding}) \times 100\%}{(2)}
\]

**Physical compatibility study with sodium chloride injection, glucose injection, and sterile water**
The NIM-EPC-SGC-MMs and NIM injection were diluted by certain degrees – 10-fold, 100-fold, 500-fold – by sodium chloride injection, glucose injection, and sterile water, respectively. Each sample was placed in a 10 mL tube and examined for observable small particles and low-level haze\(^10\) in normal fluorescent light from a Tyndall beam (high-intensity mono-directional light source) using the unaided eye. As a standard, the turbidity of each sample was measured. All of the samples were kept at room temperature and observed at fixed time points (0, 0.5, 1, 5 and 10 hours).

**In vivo studies in rats**
Ten male Wistar rats (200 ± 20 g) were randomly divided into two groups, with five rats in each group. Rats were fasted overnight but supplied with water before the experiment. The NIM injection and NIM-EPC-SGC-MMs, with the same mass concentration of NIM, were administered by intravenous injection through the tail vein at a dose of 2 mg/kg.

After administration, blood was collected from the ocular vein at predetermined time points (5, 15, 30, 45, 60, 120, 240, 300 minutes). Plasma samples (0.5 mL) were placed into
heparinized centrifuge tubes; plasma samples (100 µL) were collected immediately following centrifugation at 1296 × g for 10 min and then stored at −20°C until further use.

Determination of NIM in plasma samples by HPLC
The concentration of NIM in blood was determined by a reverse-phase HPLC method.\(^1\) In brief, 100 µL of plasma was mixed with 25 µL of internal standard (nimodipine at a concentration of 0.0020 mg/mL in methanol), followed by vortex mixing for 1 minute. Then, 50 µL of 1 mol/L NaOH was added and the mixture was extracted with 0.4 mL N-hexane-ethyl ether (1:1) twice. After vortex for 1 minute was added and the mixture was extracted with 0.4 mL of 1 mol/L NaOH. The residue was dissolved into 100 µL mobile phase after vortexing for 30 seconds and centrifuged at 12,000 × g for 10 minutes, the supernatant was collected and combined, followed by evaporation under nitrogen at 50°C. The residue was dissolved into 100 µL mobile phase after vortexing for 30 seconds and centrifuged at 12,000 × g for 10 minutes sequentially; 50 µL of the resultant supernatant was subjected to HPLC analysis. A reverse-phase column (C18, 250 × 4.6 mm, 5 µm) was used with a security guard column (C18, 10 × 4 mm, 5 µm), (Phenomenex, Torrance, CA). Under a column temperature of 35°C, the mobile phase consisted of a mixture of acetonitrile – 0.05 mol/L ammonium acetate (60:40). The flow rate was 1.0 mL/min and the detection wavelength was 358 nm.

Vascular irritability study in rabbits
Six male rabbits (weight 2.5–3.0 kg) were randomly divided into two groups. One group was injected with NIM-EPC-SGC-MMs and sodium chloride injection. The other group was injected with the commercial NIM injection and sodium chloride injection as a control. Each group was injected according to a clinical dosing regimen of 0.4 mg/kg for 5 days. In brief, animals in the first group were administered an NIM injection of clinical concentration via ear vein infusion on the right and received a sodium chloride injection on the left. The second group was injected with NIM-EPC-SGC-MMs of clinical concentration via vein infusion on the right ear and received a sodium chloride injection on the left. Visual observations of the injection site and surrounding tissue were made and recorded as pathological samples at intervals until 48 hours; at that time, each group was sacrificed. After being fixed in 10% v/v formaldehyde in physiological saline for 48 hours, the obtained samples were serially dehydrated by different concentrations of ethanol (100%, 95%, 85%, 70%, 2–5 minutes for each concentration). The dehydrated samples were embedded in paraffin and cut and stained using hematoxylin and eosin. All sections were observed at × 100 magnification with an Axiovert200 (Zeiss, Oberkochen, Germany), and pathological changes were analyzed and evaluated.

Statistical analysis
The measured plasma concentration data were analyzed using non-linear regression analysis with the use of Drug and Statistics Software (DAS 2.0; Mathematical Pharmacology Professional Committee of China, Shanghai, China); the best compartment model for estimating pharmacokinetic parameters was then determined. After we analyzed the Student’s t-test results of the two groups, we determined that a P value < 0.05 would be considered statistically significant.

Results
Determination of solubilizing efficiency of NIM-EPC-SGC-MMs in different formulations
The influence of the EPC/SGC mass concentration ratio on the solubilizing efficiency of the NIM-EPC-SGC-MMs (NIM concentration was kept at 0.5 mg/mL) is shown in Figure 2. When the EPC/SGC mass concentration ratio decreased from 1:0.7 to 1:1, a significant increase in NIM solubilizing efficiency was observed. However, a further decrease in the EPC/SGC mass concentration ratio (from 1:1 to 0:1) did not improve NIM solubilizing efficiency – remarkably, it reduced the solubilizing efficiency. The EPC/SGC concentration ratio of 1:1 was used for the subsequent studies, as the solubilizing efficiency under such conditions could be up to 96.40%.

When the mass concentration of NIM in water was set at 0.5 mg/mL, the influence of the total concentration of SGC and EPC on NIM solubilizing efficiency was also

![Figure 2 Influence of the mass concentration ratio of EPC and SGC on NIM solubilizing efficiency at 25°C (n = 3).](image-url)

Abbreviations: EPC, egg phosphatidylcholine; SGC, sodium glycocholate; NIM, nimodipine.
investigated. As shown in Figure 3, NIM solubilizing efficiency was improved by increasing the total concentration of SGC and EPC in the MM system. The solubilizing efficiency did not further improve when the total concentration of SGC and EPC was higher than 40 mg/mL.

The effect of NIM concentration on the stability of the NIM-EPC-SGC-MMs is shown in Table 1. The results showed that NIM concentration could affect the stability of the NIM-EPC-SGC-MMs. The limiting concentration of NIM in this optimized EPC-SGC-MM system was 0.5 mg/mL, since further increases in the concentration of NIM resulted in the instability of the NIM-EPC-SGC-MMs, as indicated by the separation of NIM from the formulation.

The influence of pH value on the solubilizing efficiency of NIM in EPC-SGC-MMs is shown in Figure 4. An increase in pH value of the EPC-SGC-MM solvent could dramatically enhance the solubilizing efficiency of NIM when the pH value was between 2 and 6. With pH values higher than 6, the solubilizing efficiency of NIM showed a slight fluctuation. Nevertheless, phospholipids in neutral pH (6.5) have the greatest stability. A pH of 7.4 is relevant to physiology. When pH values were about 7.4, the solubilizing efficiency could be up to 96.40%. Hence, pH was settled at approximately 7.4.

The effect of ionic strength on the solubilizing efficiency of NIM-EPC-SGC-MMs was not studied because physiological saline was the only dispersion solution.

**CMC determination**

With Origin 8.5 software, pyrene 1:3 ratio plots could be adequately described by the Boltzmann-type approach (Figure 5), which is shown by the following equation:

\[
y = \frac{A_1 - A_2}{1 + e^{(x-x_0)/\Delta x}} + A_2, \tag{3}
\]

![Figure 3 Influence of the total concentration of SGC and EPC on NIM solubilizing efficiency at 25°C (n = 3).](image)

**Abbreviations:** EPC, egg phosphatidylcholine; SGC, sodium glycocholate; NIM, nimodipine.

![Figure 4 Influence of pH value of dispersed medium on NIM solubilizing efficiency at 25°C (n = 3).](image)

**Abbreviation:** NIM, nimodipine.

*Table 1 Influence of NIM concentration on the stability of NIM-EPC-SGC-MMs*

<table>
<thead>
<tr>
<th>NIM (mg/mL)</th>
<th>EPC + SGC (mg)</th>
<th>Time (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0 1 24 48 72</td>
</tr>
<tr>
<td>0.5</td>
<td>40</td>
<td>Y Y Y Y Y</td>
</tr>
<tr>
<td>0.8</td>
<td>40</td>
<td>Y Y Y Y C</td>
</tr>
<tr>
<td>1.0</td>
<td>40</td>
<td>Y Y Y C C</td>
</tr>
<tr>
<td>1.6</td>
<td>40</td>
<td>C C C C C</td>
</tr>
<tr>
<td>2.0</td>
<td>40</td>
<td>C C C C C</td>
</tr>
</tbody>
</table>

**Notes:** Y = settled solution; C = NIM separating out; n = 3.

**Abbreviations:** NIM, nimodipine; EPC, egg phosphatidylcholine; SGC, sodium glycocholate; NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.

![Figure 5 Plot of the fluorescence of pyrene I/II intensity ratio versus concentration of EPC/SGC mixed micelles (mass ratio 1:1) in distilled water at 25°C (n = 3).](image)

**Abbreviations:** EPC, egg phosphatidylcholine; SGC, sodium glycocholate; I/II, intensity of the third to the first peak (372 and 383 nm) of pyrene.
where the variable $y$ is the pyrene 1:3 ratio value, the independent variable ($\chi$) is the total concentration of surfactant, and $A_1$ and $A_2$ correspond to the upper and lower limits of sigmoid, respectively; $\chi_c$ is the center of the sigmoid and $\Delta \chi$ is directly related to the independent variable occurrence. As shown in Figure 5, the shape of the plots exhibited a typically sigmoidal decrease. For the Boltzmann-type equation, the values for $A_1$, $A_2$, $\chi_c$, and $\Delta \chi$ were 1.55, 0.85, −3.02, and 0.36, respectively. $R^2$ was 0.99, indicating that the Boltzmann-type model was consistent with the typically sigmoidal decrease of the plot. As the value of $\chi_c/\Delta \chi$ was less than 10, $\chi_c$ should be the CMC value. Consequently, the CMC value of EPC/SGC (1:1) was 0.0095 mg/mL.

### In vivo studies in rats

The mean plasma concentration–time curves of NIM after intravenous administration of NIM injection and NIM-EPC-SGC-MMs to rats (equivalent to 2 mg/kg of NIM; $n = 5$), are shown in Figure 7. The results indicate that the NIM-EPC-SGC-MMs and NIM injection share the same trend. For both preparations, in the first 45 minutes, the elimination of NIM from the blood was rapid then became very slow after that. The concentration of NIM was at the minimum of 300 minutes and then could no longer be detected. Table 3 shows the main pharmacokinetic parameters in rats after intravenous injection of NIM injection and NIM-EPC-SGC-MMs (calculated with DAS 2.0 software). The area under the concentration–time curve from time zero to infinity, maximum concentration following administration, mean retention time, and half-life of NIM between the NIM-EPC-SGC-MM group and NIM injection group showed no significant differences ($P > 0.05$), indicating that the two formulations were bioequivalent.

### Vascular irritability study in rabbits

The rabbit-ear vein irritation test was processed to evaluate the irritation of NIM-EPC-SGC-MMs and sodium chloride injection versus NIM injection. Compared with the NIM injection, the NIM-EPC-SGC-MM formulation-treated rabbit group did not show deep respiration. In addition, during infusion of the NIM injection, the rabbits struggled more frequently than those in the NIM-EPC-SGC-MMs and sodium chloride injection group. After 5-days of infusion, the ear vein of the rabbits in the NIM injection group showed vascular congestion and vascular lines were unclear. In this group, edema appeared at the surrounding tissue. In contrast, the ear vein of rabbits injected with NIM-EPC-SGC-MMs and sodium chloride injection only had slight phlebectasia, which disappeared 30 minutes after injection.

We viewed these results in histopathological slices, as shown in Figure 8. The histopathological damage caused by the NIM injection was observed microscopically as vasodilation, hemorrhage and degeneration around the vein wall, degeneration of the vein wall, edema around the vein, inflammatory cell infiltration around the vein, and endothelial cell swelling (Figure 8A). However, the results for NIM-EPC-SGC-MMs and sodium chloride injection (Figure 8B and 8C) show no histopathological damage.

### Discussion

It has been demonstrated that the PC-BS-MM system has great potential to improve the solubility of poorly water-soluble drugs as a novel delivery vehicle, especially in...
solubilization of some lipophilic drugs. Among different 
BS, SGC has the highest capacity to solubilize soybean 
lecithin (SPC), and EPC was solubilized to a higher 
extent than SPC. The solubility of NIM in water was 
0.468 ± 0.009 mg/mL after the formation of optimized 
NIM-EPC-SGC-MMs. The solubility of NIM in EPC-
SGC-MMs was significantly improved, about 120-fold 
higher than that of free NIM with a water solubility of 
3.86 µg/mL, which suggests that the NIM-EPC-SGC-MM 
system is a promising strategy for improving the solubility 
of NIM in water.

To optimize the NIM-EPC-SGC-MM preparation, the 
four main parameters that may affect the solubilization 
potential of the system were studied: (1) EPC/SGC mass 
concentration ratio, (2) the total concentration of EPC and 
SGC, (3) the dose of NIM, and (4) the pH value.

First, the EPC/SGC mass concentration ratio was evaluated 
and the solubilizing efficiency was employed as the evaluation 
parameter. The highest solubilizing efficiency of NIM 
was obtained when the EPC/SGC mass concentration ratio 
was 1:1. The EPC/SGC mass concentration ratio (1:1) was 
equal to the EPC mol fraction of 0.6, and EPC at a maximum 
mol fraction of 0.6 could be incorporated in SGC to form 
a clear mixed-micellar solution. A further decrease in the 
amount of EPC (EPC/SGC mass concentration ratio from 
1:1 to 0:1) did not improve but, remarkably, reduced NIM

![Size distribution by intensity](image)

**Figure 6** (A) Size and size distribution of the optimal NIM-EPC-SGC-MMs; (B) transmission electron micrograph of NIM-EPC-SGC-MMs (scale bar = 50 nm). 
**Abbreviation:** NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.

![Mean plasma concentration–time curves of NIM after intravenous injection of NIM injection and NIM-EPC-SGC-MMs in rats (n = 5).](image)

**Figure 7** Mean plasma concentration–time curves of NIM after intravenous injection of NIM injection and NIM-EPC-SGC-MMs in rats (n = 5).

**Note:** Each point represents mean ± standard deviation.

**Abbreviations:** NIM, nimodipine; NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.
Table 3 The main pharmacokinetic parameters of the NIM injection and NIM-EPC-SGC-MMs in rats

<table>
<thead>
<tr>
<th>Parameter</th>
<th>NIM-EPC-SGC-MMs</th>
<th>NIM injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC_{0-24h} (µg·mL⁻¹·min)</td>
<td>434.851 ± 30.886</td>
<td>392.903 ± 34.172</td>
</tr>
<tr>
<td>AUC_{0-24h} (µg·mL⁻¹·min)</td>
<td>461.911 ± 26.984</td>
<td>427.848 ± 23.123</td>
</tr>
<tr>
<td>MRT_{0-24h} (min)</td>
<td>62.722 ± 5.064</td>
<td>61.999 ± 9.887</td>
</tr>
<tr>
<td>MRT_{0-24h} (min)</td>
<td>83.996 ± 9.373</td>
<td>95.386 ± 37.737</td>
</tr>
<tr>
<td>C_{max} (µg/mL)</td>
<td>10.214 ± 1.136</td>
<td>9.144 ± 0.797</td>
</tr>
<tr>
<td>T_{1/2} (min)</td>
<td>84.312 ± 6.655</td>
<td>102.394 ± 46.483</td>
</tr>
<tr>
<td>CL_{d} (mL·min⁻¹·g)</td>
<td>0.004</td>
<td>0.005</td>
</tr>
</tbody>
</table>

Notes: Data reported as means ± standard deviation; n = 5.
Abbreviations: AUC, area under the curve; MRT, mean retention time; NIM-EPC-SGC-MMs, nimodipine-egg phosphatidylcholine-sodium glycocholate-mixed micelles.

Regarding the effect of the total concentration of SGC and EPC on the solubility of NIM, the results showed that the optimum total concentration for the NIM-EPC-SGC-MMs was 40 mg/mL. According to the theory of micelle formation, PC-BS-MM formation is associated with the CMC, spontaneous curvature, and chemical structure of different BS and EPC. With an increase in the total concentration of SGC and EPC, the amount of single micelles increased and resulted in an improvement of the solubility of NIM. However, when the NIM within the formulation was all solubilized, the solubilizing efficiency did not improve further when more SGC and EPC were added. In addition, the relatively high solubilizing efficiency achieved by a lower total concentration of SGC and EPC could avoid the administration of redundant excipients.

The formation of drug-loaded micelles is significantly related to the properties of the drug, such as polarity; polarization degree; chain length; chain branching; and molecular size, shape, and structure. As shown by systematic research, the structure of PC-BS-MMs is widely accepted as a "mixed disk model." In this model, the MM consists of a disk-like core in which BS and phospholipids interact, and BS surround its perimeter. Drugs are generally inserted into the micelle hydrophobic core or peripheral hydrophilic micellar palisade layer. Like benzodiazepines, the planar aromatic ring of NIM contributes to the insertion of drug molecules into the lipophilic core of micelles. This corresponds to our results showing that NIM solubility improved when the lipophilic component increased with a greater proportion of EPC. The limiting concentration of NIM was 0.5 mg/mL in this optimized EPC-SGC-MM system. When the concentration of NIM was more than 0.5 mg/mL, the excess NIM would be temporarily stable in the hydrophilic micellar palisade layer; however, it would gradually separate out from the MM system, as a result of the many oxygen and nitrogen atoms in the NIM molecule, which can easily form hydrogen bonds with water.
Under ionization conditions, BS have a strong solubilization effect.15–18 The pH value of glycocholic acid is 4.4.15 When the pH was below 4.4, glycocholic acid would precipitate. Thus, when the pH value increased from 2 to 6, resulting in an increased amount of ionized SGC, the solubilizing efficiency of NIM in the EPC-SGC-MMs was significantly enhanced. Therefore, considering the solubilizing efficiency, the stability of phospholipids,31 and physiological relevance, the pH value was adjusted to 7.4; this moderate pH value scale was applied to the preparation of the NIM-EPC-SGC-MMs.

We later analyzed some characteristics of the optimized formulation of the NIM-EPC-SGC-MMs, such as particle size, morphology, solubility, solubilizing efficiency, and drug loading. The narrow peak of size distribution and the morphological spherical shape indicated that the NIM-EPC-SGC-MMs were relatively uniform and monodisperse.

The pyrene 1:3 ratio method has been reported as one of the most popular methods for measuring the CMC values of both pure micelle solutions and MMs.32,33,38,39 Pyrene monomer emission spectra are related to vibronic fine structures, whose intensities are heavily dependent on the polarity of the environment. As a hydrophobic molecule with low aqueous solubility (–0.3 µM), pyrene was sensitive to a more hydrophobic environment.38 While the pyrene was solubilized in micelles, which resulted in the formation of hydrophobic domains, a significant decrease of I3/I3 ratio was observed.39 The I3/I3 ratio became finally steady with high surfactant concentration, proving that the pyrene was in a totally hydrophobic environment.

A physical compatibility study with sodium chloride injection, glucose injection, and sterile water was performed to evaluate the safety of the NIM-EPC-SGC-MMs for clinical use. When the NIM injection is diluted, NIM crystals usually appear, owing to the decrease of the organic solvent proportion, which is dangerous for patients. Using EPC-SGC-MMs, NIM could be loaded into the micelle hydrophobic core. During dilution of NIM-EPC-SGC-MMs, the stability of the NIM-EPC-SGC-MMs was associated with the CMC. The entrapped NIM would not separate out from the MM system even when it was diluted 500-fold with the three injection solutions tested and the final total concentration of EPC and SGC was 0.8 mg/mL, suggesting that the concentration of the EPC-SGC-MMs was above the CMC in a wide dilution range. This showed that NIM-EPC-SGC-MMs were physically compatible with these injection solutions.

Pharmacokinetic study in vivo was also performed to further understand the characteristics of NIM-EPC-SGC-MMs. No significant difference was found in the main pharmacokinetic parameters between NIM injection and NIM-EPC-SGC-MMs. This may be due to the quick release of NIM from the MM system when administered by intravenous injection into the blood. To the best of our knowledge, the NIM-EPC-SGC-MM system was in dynamic equilibrium. Moreover, the plasma protein-binding rate of NIM was 97%–99%. Such a high affinity of NIM to plasma protein could extract NIM from NIM-EPC-SGC-MMs. As free NIM in the NIM injection was also bound with plasma protein, the two formulations share almost the same pharmaceutical profile.

A vascular irritability study in rabbits was performed to evaluate the safety of the formulations. The NIM injection caused a very serious vascular irritability in the ear vein of rabbits, which is in accordance with the results of clinical application.12 In contrast, NIM-EPC-SGC-MMs and sodium chloride injection caused almost no vascular irritability. The most reasonable explanation for the irritability of the NIM injection is the effect of the ethanol.11 Moreover, NIM could expand the blood vessel, resulting in increased vascular permeability.40 Increased vascular permeability would lead to the leakage of plasma, drugs, and ethanol. For treatment of subarachnoid hemorrhage, patients are given a long-term dosage regimen of about 10 hours duration for a continuous 10 to 14 days.41 Clearly, the high percentage of ethanol would cause great pain, leading to noncompliance.11 Consequently, ethanol and leak damage could be the main causes of the vascular irritation. NIM-EPC-SGC-MMs and sodium chloride injection would not have the undesired side effects associated with the mixed solvent.

Conclusion
In this study, NIM-EPC-SGC-MMs were prepared using the coprecipitation method. After optimization of the novel formulation, NIM-EPC-SGC-MMs exhibited suitable particle size and high NIM water solubility. NIM-EPC-SGC-MMs were also physically compatible with sodium chloride injection, glucose injection, and sterile water at room temperature for up to 10 hours. Furthermore, the NIM-EPC-SGC-MMs and NIM injection exhibited almost the same pharmacokinetics. There was nearly no vascular irritation caused by the NIM-EPC-SGC-MMs, solving the main problem of NIM intravenous clinical application. As a result, the NIM-EPC-SGC-MM system has been proven an attractive method for the intravenous administration of NIM.

Thus, with remarkable improvement in the water solubility of NIM and injection safety, NIM-EPC-SGC-MMs may
be a promising replacement for the NIM injection, which contains the organic solvent ethanol. In addition, NIM-EPC-SGC-MMs can be prepared by a simple and convenient technology, therefore have the potential to be industrially produced on a large-scale.

Acknowledgments
This work was funded by the National Basic Research Program of China (973 program, No 2009CB930300) and supported by a grant from the National S and T Major Project of China (Grant No 2011ZX09501-001-01). The authors thank Rasa Hamilton (H Lee Moffitt Cancer Center, FL), Jianfeng Han, Qiang Peng, and Sanjun Shi for editorial assistance.

Disclosure
The authors report no conflicts of interest in this work.

References


